1.Updates on Prevention of Hemorrhagic and Lacunar Strokes.
Hsin Hsi TSAI ; Jong S KIM ; Eric JOUVENT ; M Edip GUROL
Journal of Stroke 2018;20(2):167-179
Intracerebral hemorrhage (ICH) and lacunar infarction (LI) are the major acute clinical manifestations of cerebral small vessel diseases (cSVDs). Hypertensive small vessel disease, cerebral amyloid angiopathy, and hereditary causes, such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), constitute the three common cSVD categories. Diagnosing the underlying vascular pathology in these patients is important because the risk and types of recurrent strokes show significant differences. Recent advances in our understanding of the cSVD-related radiological markers have improved our ability to stratify ICH risk in individual patients, which helps guide antithrombotic decisions. There are general good-practice measures for stroke prevention in patients with cSVD, such as optimal blood pressure and glycemic control, while individualized measures tailored for particular patients are often needed. Antithrombotic combinations and anticoagulants should be avoided in cSVD treatment, as they increase the risk of potentially fatal ICH without necessarily lowering LI risk in these patients. Even when indicated for a concurrent pathology, such as nonvalvular atrial fibrillation, nonpharmacological approaches should be considered in the presence of cSVD. More data are emerging regarding the presentation, clinical course, and diagnostic markers of hereditary cSVD, allowing accurate diagnosis, and therefore, guiding management of symptomatic patients. When suspicion for asymptomatic hereditary cSVD exists, the pros and cons of prescribing genetic testing should be discussed in detail in the absence of any curative treatment. Recent data regarding diagnosis, risk stratification, and specific preventive approaches for both sporadic and hereditary cSVDs are discussed in this review article.
Anticoagulants
;
Atrial Fibrillation
;
Blood Pressure
;
CADASIL
;
Cerebral Amyloid Angiopathy
;
Cerebral Hemorrhage
;
Cerebral Small Vessel Diseases
;
Diagnosis
;
Genetic Testing
;
Humans
;
Pathology
;
Stroke
;
Stroke, Lacunar*
2.Spontaneous Spinal Epidural Hematoma: A Retrospective Study on Prognostic Factors and Review of the Literature.
Mark FEDOR ; Eric S KIM ; Kai DING ; J Paul MUIZELAAR ; Kee D KIM
Korean Journal of Spine 2011;8(4):272-282
OBJECTIVES: The spontaneous spinal epidural hematoma (SSEH) is a rare clinical entity. Patients typically present with sudden onset back pain followed by neurological deficits. METHODS: Diagnosis of SSEH is usually made with MRI and standard treatment is surgical evacuation. In 1996, Groen published the most comprehensive review on the SSEH in which he analyzed 333 cases. We review 104 cases of SSEH presented in the English literature since the last major review and add three of our own cases, for a total of 107 cases. RESULTS: Our patients presented with back pain and neurologic deficits. Two made excellent functional recovery with prompt surgical decompression while one continued to have significant deficits despite evacuation. Better postoperative outcome was associated with less initial neurological dysfunction, shorter time to operation from symptom onset and male patients. CONCLUSION: We discuss the etiology of SSEH and report current trends in diagnosis, treatment, and outcome.
Back Pain
;
Decompression, Surgical
;
Hematoma, Epidural, Spinal
;
Humans
;
Male
;
Neurologic Manifestations
;
Retrospective Studies
3.Percutaneous transmyocardial revascularization induces angiogenesis: a histologic and 3-dimensional micro computed tomography study.
Hyuck Moon KWON ; Bum Kee HONG ; Gil Jin JANG ; Dong Soo KIM ; Eui Young CHOI ; In Jai KIM ; Charles J MCKENNA ; Eric L RITMAN ; Robert S SCHWARTZ
Journal of Korean Medical Science 1999;14(5):502-510
The purpose of this study was to visualize the spatial patterns and connection of channels created after percutaneous transmyocardial revascularization (PTMR) in normal porcine hearts, and to estimate the relative contributions of transmyocardial and coronary perfusion. Six pigs underwent PTMR creating channels using radiofrequency ablative energy. Three-dimensional computed tomography imaging of channels 1 hr after PTMR showed the direct connection of PTMR channels to the myocardial capillary network and to epicardial coronary vessels. In the heart, examined 28 day after PTMR, there was a fine, extensive, network of microvessels originating from the site of the original PTMR channel, also connecting the left ventricular cavity to myocardial capillaries. Histopathologic examination of the 1-hr specimens showed numerous regions of myocardial hemorrhage and associated inflammatory cell infiltration. In the 28-day specimens, newly developed new vascular network suggested neovascularization within the core of these channel remnants. The immunoreactivity for basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were intense within myocardium and neovascular structure surrounding PTMR channel remnants. The vascular connections occur by direct communication with existing myocardial vasculature acutely, and angiogenesis in these channel remnant chronically.
Animal
;
Coronary Angiography
;
Coronary Circulation
;
Coronary Vessels/pathology
;
Heart/radiography*
;
Heart Ventricle/radiography
;
Image Enhancement/methods
;
Immunohistochemistry
;
Myocardial Revascularization/methods*
;
Myocardium/pathology*
;
Neovascularization, Pathologic/radiography
;
Neovascularization, Pathologic/pathology*
;
Perfusion
;
Swine
;
Tomography, X-Ray Computed
4.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
5.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
6.Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
Janice S. KWON ; Helen MCTAGGART-COWAN ; Sarah E. FERGUSON ; Vanessa SAMOUËLIAN ; Eric LAMBAUDIE ; Frédéric GUYON ; John TIDY ; Karin WILLIAMSON ; Noreen GLEESON ; Cor de KROON ; Willemien van DRIEL ; Sven MAHNER ; Lars HANKER ; Frédéric GOFFIN ; Regina BERGER ; Brynhildur EYJÓLFSDÓTTIR ; Jae-Weon KIM ; Lori A. BROTTO ; Reka PATAKY ; Shirley S.T. YEUNG ; Kelvin K.W. CHAN ; Matthew C. CHEUNG ; Juliana UBI ; Dongsheng TU ; Lois E. SHEPHERD ; Marie PLANTE
Journal of Gynecologic Oncology 2024;35(6):e117-
Objective:
SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health.The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
Methods:
Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
Results:
Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs.radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
Conclusion
Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
7.Regenerative Therapy in Erectile Dysfunction:A Survey on Current Global Practice Trends and GAF Expert Recommendations
Manaf Al HASHIMI ; Germar-M PINGGERA ; Taymour MOSTAFA ; Amarnath RAMBHATLA ; Taha HAMODA ; Rupin SHAH ; Eric CHUNG ; Ahmed HARRAZ ; Mohamed ARAFA ; Tuncay TOPRAK ; Omer RAHEEM ; Carlo GIULIONI ; Ponco BIROWO ; Luca BOERI ; Yassir JASSIM ; Priyank KOTHARI ; Ranjit VISHWAKARMA ; Bahadir SAHIN ; Widi ATMOKO ; Safar GAMIDOV ; Cesar ROJAS-CRUZ ; Darren KATZ ; Adriano FREGONESI ; Nazim GHERABI ; Armand ZINI ; Christopher Chee Kong HO ; Mohamed S. AL-MARHOON ; Marlon MARTINEZ ; Giorgio Ivan RUSSO ; Ayman RASHED ; Gian Maria BUSETTO ; Edmund KO ; Hyun Jun PARK ; Selahittin CAYAN ; Ramadan SALEH ; Osvaldo RAJMIL ; Dong Suk KIM ; Giovanni COLPI ; Ryan SMITH ; Maged RAGAB ; Ates KADIOGLU ; Quang NGUYEN ; Kadir BOCU ; Ahmed EL-SAKKA ; Charalampos THOMAS ; Hussain M ALNAJJAR ; Hiva ALIPOUR ; Ashok AGARWAL
The World Journal of Men's Health 2025;43(2):359-375
Purpose:
This study aimed to examine current global practices in regenerative therapy (RT) for erectile dysfunction (ED) and to establish expert recommendations for its use, addressing the current lack of solid evidence and standardized guidelines.
Materials and Methods:
A 39-question survey was developed by senior Global Andrology Forum (GAF) experts to comprehensively cover clinical aspects of RT. This was distributed globally via a secure online Google Form to ED specialists through the GAF website, international professional societies, and social media, the responses were analyzed and presented for frequencies as percentages. Consensus on expert recommendations for RT use was achieved using the Delphi method.
Results:
Out of 479 respondents from 62 countries, a third reported using RT for ED. The most popular treatment was low-intensity shock wave therapy (54.6%), followed by platelet-rich plasma (24.5%) and their combination (14.7%), with stem cell therapy being the least used (3.7%). The primary indication for RT was the refractory or adverse effects of PDE5 inhibitors, with the best effectiveness reported in middle-aged and mild-to-moderate ED patients. Respondents were confident about its overall safety, with a significant number expressing interest in RT’s future use, despite pending guidelines support.
Conclusions
This inaugural global survey reveals a growing use of RT in ED treatment, showcasing its diverse clinical applications and potential for future widespread adoption. However, the lack of comprehensive evidence and clear guidelines requires further research to standardize RT practices in ED treatment.
8.Regenerative Therapy in Erectile Dysfunction:A Survey on Current Global Practice Trends and GAF Expert Recommendations
Manaf Al HASHIMI ; Germar-M PINGGERA ; Taymour MOSTAFA ; Amarnath RAMBHATLA ; Taha HAMODA ; Rupin SHAH ; Eric CHUNG ; Ahmed HARRAZ ; Mohamed ARAFA ; Tuncay TOPRAK ; Omer RAHEEM ; Carlo GIULIONI ; Ponco BIROWO ; Luca BOERI ; Yassir JASSIM ; Priyank KOTHARI ; Ranjit VISHWAKARMA ; Bahadir SAHIN ; Widi ATMOKO ; Safar GAMIDOV ; Cesar ROJAS-CRUZ ; Darren KATZ ; Adriano FREGONESI ; Nazim GHERABI ; Armand ZINI ; Christopher Chee Kong HO ; Mohamed S. AL-MARHOON ; Marlon MARTINEZ ; Giorgio Ivan RUSSO ; Ayman RASHED ; Gian Maria BUSETTO ; Edmund KO ; Hyun Jun PARK ; Selahittin CAYAN ; Ramadan SALEH ; Osvaldo RAJMIL ; Dong Suk KIM ; Giovanni COLPI ; Ryan SMITH ; Maged RAGAB ; Ates KADIOGLU ; Quang NGUYEN ; Kadir BOCU ; Ahmed EL-SAKKA ; Charalampos THOMAS ; Hussain M ALNAJJAR ; Hiva ALIPOUR ; Ashok AGARWAL
The World Journal of Men's Health 2025;43(2):359-375
Purpose:
This study aimed to examine current global practices in regenerative therapy (RT) for erectile dysfunction (ED) and to establish expert recommendations for its use, addressing the current lack of solid evidence and standardized guidelines.
Materials and Methods:
A 39-question survey was developed by senior Global Andrology Forum (GAF) experts to comprehensively cover clinical aspects of RT. This was distributed globally via a secure online Google Form to ED specialists through the GAF website, international professional societies, and social media, the responses were analyzed and presented for frequencies as percentages. Consensus on expert recommendations for RT use was achieved using the Delphi method.
Results:
Out of 479 respondents from 62 countries, a third reported using RT for ED. The most popular treatment was low-intensity shock wave therapy (54.6%), followed by platelet-rich plasma (24.5%) and their combination (14.7%), with stem cell therapy being the least used (3.7%). The primary indication for RT was the refractory or adverse effects of PDE5 inhibitors, with the best effectiveness reported in middle-aged and mild-to-moderate ED patients. Respondents were confident about its overall safety, with a significant number expressing interest in RT’s future use, despite pending guidelines support.
Conclusions
This inaugural global survey reveals a growing use of RT in ED treatment, showcasing its diverse clinical applications and potential for future widespread adoption. However, the lack of comprehensive evidence and clear guidelines requires further research to standardize RT practices in ED treatment.
9.Regenerative Therapy in Erectile Dysfunction:A Survey on Current Global Practice Trends and GAF Expert Recommendations
Manaf Al HASHIMI ; Germar-M PINGGERA ; Taymour MOSTAFA ; Amarnath RAMBHATLA ; Taha HAMODA ; Rupin SHAH ; Eric CHUNG ; Ahmed HARRAZ ; Mohamed ARAFA ; Tuncay TOPRAK ; Omer RAHEEM ; Carlo GIULIONI ; Ponco BIROWO ; Luca BOERI ; Yassir JASSIM ; Priyank KOTHARI ; Ranjit VISHWAKARMA ; Bahadir SAHIN ; Widi ATMOKO ; Safar GAMIDOV ; Cesar ROJAS-CRUZ ; Darren KATZ ; Adriano FREGONESI ; Nazim GHERABI ; Armand ZINI ; Christopher Chee Kong HO ; Mohamed S. AL-MARHOON ; Marlon MARTINEZ ; Giorgio Ivan RUSSO ; Ayman RASHED ; Gian Maria BUSETTO ; Edmund KO ; Hyun Jun PARK ; Selahittin CAYAN ; Ramadan SALEH ; Osvaldo RAJMIL ; Dong Suk KIM ; Giovanni COLPI ; Ryan SMITH ; Maged RAGAB ; Ates KADIOGLU ; Quang NGUYEN ; Kadir BOCU ; Ahmed EL-SAKKA ; Charalampos THOMAS ; Hussain M ALNAJJAR ; Hiva ALIPOUR ; Ashok AGARWAL
The World Journal of Men's Health 2025;43(2):359-375
Purpose:
This study aimed to examine current global practices in regenerative therapy (RT) for erectile dysfunction (ED) and to establish expert recommendations for its use, addressing the current lack of solid evidence and standardized guidelines.
Materials and Methods:
A 39-question survey was developed by senior Global Andrology Forum (GAF) experts to comprehensively cover clinical aspects of RT. This was distributed globally via a secure online Google Form to ED specialists through the GAF website, international professional societies, and social media, the responses were analyzed and presented for frequencies as percentages. Consensus on expert recommendations for RT use was achieved using the Delphi method.
Results:
Out of 479 respondents from 62 countries, a third reported using RT for ED. The most popular treatment was low-intensity shock wave therapy (54.6%), followed by platelet-rich plasma (24.5%) and their combination (14.7%), with stem cell therapy being the least used (3.7%). The primary indication for RT was the refractory or adverse effects of PDE5 inhibitors, with the best effectiveness reported in middle-aged and mild-to-moderate ED patients. Respondents were confident about its overall safety, with a significant number expressing interest in RT’s future use, despite pending guidelines support.
Conclusions
This inaugural global survey reveals a growing use of RT in ED treatment, showcasing its diverse clinical applications and potential for future widespread adoption. However, the lack of comprehensive evidence and clear guidelines requires further research to standardize RT practices in ED treatment.
10.Regenerative Therapy in Erectile Dysfunction:A Survey on Current Global Practice Trends and GAF Expert Recommendations
Manaf Al HASHIMI ; Germar-M PINGGERA ; Taymour MOSTAFA ; Amarnath RAMBHATLA ; Taha HAMODA ; Rupin SHAH ; Eric CHUNG ; Ahmed HARRAZ ; Mohamed ARAFA ; Tuncay TOPRAK ; Omer RAHEEM ; Carlo GIULIONI ; Ponco BIROWO ; Luca BOERI ; Yassir JASSIM ; Priyank KOTHARI ; Ranjit VISHWAKARMA ; Bahadir SAHIN ; Widi ATMOKO ; Safar GAMIDOV ; Cesar ROJAS-CRUZ ; Darren KATZ ; Adriano FREGONESI ; Nazim GHERABI ; Armand ZINI ; Christopher Chee Kong HO ; Mohamed S. AL-MARHOON ; Marlon MARTINEZ ; Giorgio Ivan RUSSO ; Ayman RASHED ; Gian Maria BUSETTO ; Edmund KO ; Hyun Jun PARK ; Selahittin CAYAN ; Ramadan SALEH ; Osvaldo RAJMIL ; Dong Suk KIM ; Giovanni COLPI ; Ryan SMITH ; Maged RAGAB ; Ates KADIOGLU ; Quang NGUYEN ; Kadir BOCU ; Ahmed EL-SAKKA ; Charalampos THOMAS ; Hussain M ALNAJJAR ; Hiva ALIPOUR ; Ashok AGARWAL
The World Journal of Men's Health 2025;43(2):359-375
Purpose:
This study aimed to examine current global practices in regenerative therapy (RT) for erectile dysfunction (ED) and to establish expert recommendations for its use, addressing the current lack of solid evidence and standardized guidelines.
Materials and Methods:
A 39-question survey was developed by senior Global Andrology Forum (GAF) experts to comprehensively cover clinical aspects of RT. This was distributed globally via a secure online Google Form to ED specialists through the GAF website, international professional societies, and social media, the responses were analyzed and presented for frequencies as percentages. Consensus on expert recommendations for RT use was achieved using the Delphi method.
Results:
Out of 479 respondents from 62 countries, a third reported using RT for ED. The most popular treatment was low-intensity shock wave therapy (54.6%), followed by platelet-rich plasma (24.5%) and their combination (14.7%), with stem cell therapy being the least used (3.7%). The primary indication for RT was the refractory or adverse effects of PDE5 inhibitors, with the best effectiveness reported in middle-aged and mild-to-moderate ED patients. Respondents were confident about its overall safety, with a significant number expressing interest in RT’s future use, despite pending guidelines support.
Conclusions
This inaugural global survey reveals a growing use of RT in ED treatment, showcasing its diverse clinical applications and potential for future widespread adoption. However, the lack of comprehensive evidence and clear guidelines requires further research to standardize RT practices in ED treatment.